Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the number of employees at 23andMe by the end of 2025?
Less than 300 • 25%
300 to 500 • 25%
501 to 700 • 25%
More than 700 • 25%
Official reports from 23andMe or major news outlets
23andMe Cuts 200 Jobs, Discontinues Therapy Programs Ahead of Holidays
Nov 12, 2024, 02:45 PM
Genetic testing firm 23andMe (NASDAQ: ME), headquartered in South San Francisco, announced that it is reducing its workforce by about 40%, cutting over 200 jobs ahead of the holidays, as part of a restructuring program aimed at reducing costs and focusing on its core consumer business. The company is also discontinuing all therapy programs, shutting down its therapeutics division and ceasing all drug development and clinical trials, including cancer research programs. CEO Anne Wojcicki stated that the decision is intended to streamline operations and position the company for future growth. The layoffs are expected to save around $35 million but will incur up to $12 million in one-time costs. The announcement comes as the company reported declining revenue in its most recent quarter.
View original story
Significantly improved • 25%
Slightly improved • 25%
Unchanged • 25%
Declined • 25%
Internal promotion • 25%
External hire • 25%
No new CEO appointed • 25%
Anne Wojcicki remains CEO • 25%
New CEO appointed from within the company • 25%
New CEO appointed from outside the company • 25%
Interim CEO appointed • 25%
Above 50% increase • 25%
10% to 50% increase • 25%
0% to 10% increase • 25%
Decrease • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No change • 25%
Decrease • 25%
Stock increases by 10% or more • 25%
Stock remains within +/- 10% • 25%
Stock decreases by 10% or more • 25%
Stock remains volatile with no clear trend • 25%
Anne Wojcicki remains CEO • 25%
New CEO appointed from internal candidate • 25%
New CEO appointed from external candidate • 25%
Interim CEO appointed • 25%
Less than 500 employees • 25%
500 to 1000 employees • 25%
1000 to 1500 employees • 25%
More than 1500 employees • 25%
Underperforms NASDAQ • 25%
Delisted from NASDAQ • 25%
Outperforms NASDAQ • 25%
Performs on par with NASDAQ • 25%